SQZ Biotechnologies Current Ratio 2020-2022 | SQZ

SQZ Biotechnologies current ratio from 2020 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
SQZ Biotechnologies Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-06-30 $0.11B $0.03B 3.87
2022-03-31 $0.13B $0.03B 4.34
2021-12-31 $0.15B $0.03B 4.53
2021-09-30 $0.17B $0.04B 4.25
2021-06-30 $0.19B $0.04B 4.32
2021-03-31 $0.21B $0.04B 4.98
2020-12-31 $0.18B $0.05B 3.91
2020-09-30 $0.12B $0.05B 2.35
2020-06-30 $0.00B 0.00
2020-03-31 $0.00B 0.00
2019-12-31 $0.00B 0.00
2019-09-30 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.068B $0.027B
SQZ Biotechnologies Company is a clinical-stage biotechnology company. It develops transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company's prime product candidate consist SQZ-PBMC-HPV which is in clinical stage. SQZ Biotechnologies Company is based In Watertown, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $150.984B 9.16
GSK (GSK) United Kingdom $59.709B 7.17
Bio-Rad Laboratories (BIO.B) United States $12.433B 27.47
Biohaven Pharmaceutical Holding (BHVN) United States $10.873B 0.00
QIAGEN (QGEN) Netherlands $9.383B 15.71
Ginkgo Bioworks Holdings (DNA) United States $4.998B 0.00
Arcus Biosciences (RCUS) United States $1.819B 35.51
Myovant Sciences (MYOV) United Kingdom $1.614B 0.00
Emergent Biosolutions (EBS) United States $1.040B 6.03
ADC Therapeutics SA (ADCT) Switzerland $0.376B 0.00
Zymeworks (ZYME) Canada $0.305B 0.00
Enzo Biochem (ENZ) United States $0.105B 0.00
Gelesis Holdings (GLS) United States $0.081B 0.00
Ambrx Biopharma (AMAM) United States $0.041B 0.00